CAMBRIDGE, Mass., Feb. 6, 2017 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will be participating in the2017 BIO CEO & Investor Conference in New York City on Monday, February 13, 2017. During the conference, Joseph Pearlberg, M.D., Ph.D., vice president,
Additionally, Adelene Perkins, Infinity's chair and chief executive officer will provide an overview of the company on Monday, February 13, at 3:00 p.m. ET. A live webcast of Infinity's presentation will be accessible on the Investors/Media section of Infinity's website at www.infi.com and will be available for 90 days following the event.
About InfinityInfinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is developing IPI-549, an oral immuno-oncology development candidate that selectively inhibits PI3K-gamma. A Phase 1 study in patients with advanced solid tumors is ongoing. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Contact:Jaren Irene Madden, Senior Director, Investor Relations and Corporate Communications617-453-1336 or [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/infinity-to-present-at-the-2017-bio-ceo--investor-conference-300402020.html
SOURCE Infinity Pharmaceuticals, Inc.
Subscribe to our Free Newsletters!
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...
Reflux nephropathy is the scarring and damage caused to the kidneys by reverse flow of urine from ...View All